20-Hydroxyvitamin D3

20-Hydroxyvitamin D3 (20 min) acts as a substrate for mouse CYP27B1, with a 1α-hydroxylase activity of 0.135 mol product/min/mol CYP27B1^[1].
20-Hydroxyvitamin D3 (0.1-100 nM; 24 h, 48 h) dose-dependently inhibits proliferation of human HaCaT keratinocytes and HDFn, with significant effects observed at concentrations ≥0.1 nM after 24 or 48 h of treatment^[1].
20-Hydroxyvitamin D3 (0.1-100 nM; 8 h, 24 h) stimulates the expression of keratinocyte differentiation marker genes involucrin, CK10, and filaggrin in human HEKn after 8 or 24 h of treatment^[1].
20-Hydroxyvitamin D3 (100 nM; 48 h) significantly increases protein levels of involucrin, CK10, CK14, and catalase, promoting differentiation of human HEKn^[1].
20-Hydroxyvitamin D3 (1.5 h) induces VDR translocation to the nucleus in SKMEL-188 melanoma cells, with an EC₅₀ of 0.19 μM^[1].
20-Hydroxyvitamin D3 (23 h) acts as an agonist for AhR, stimulating AhR-dependent luciferase activity in reporter cells with an EC₅₀ of 39 nM^[1].
20-Hydroxyvitamin D3 (100 nM; 8 h) significantly upregulates the expression of VDR target gene CYP24A1 and AhR target genes CYP1A1 and CYP1B1 in human HEKn^[1].
20-Hydroxyvitamin D3 (100 nM; 24 h) increases the proportion of a specific CD4 T cell subpopulation (downregulated CD4, increased CD69/ICOS) in activated human PBMC^[1].
20-Hydroxyvitamin D3 (substrate-to-phospholipid ratios; 1 min kinetic assays, up to 30 min time course/product identification assays) is metabolized by rat CYP24A1 in phospholipid vesicles with a catalytic efficiency of 386 min⁻¹ (mol substrate/mol phospholipid)⁻¹, producing primarily 20,24-dihydroxyvitamin D3 and 20,25-dihydroxyvitamin D3 without generating secondary oxidized metabolites^[2].
20-Hydroxyvitamin D3 (0.1-10 nM; 2 weeks, with fresh compound added every 72 h) significantly inhibits colony formation by SKMEL-188 melanoma cells in soft agar over a 2-week period^[2].
20-Hydroxyvitamin D3 (0.1-100 nM; 7 d) inhibits proliferation of HepG2 hepatocellular carcinoma cells in a concentration-dependent manner, reducing CFU of colonies larger than 0.2 mm by 54% and colonies larger than 0.5 mm by 70% at 100 nM after 7 days of treatment^[3].
20-Hydroxyvitamin D3 (10-100 nM; 14 d) inhibits proliferation of MDA-MB-453 human breast carcinoma cells in soft agar in a concentration-dependent manner, reducing CFU of colonies larger than 0.2 mm by 54% at 100 nM and inhibiting formation of colonies larger than 1.5 mm by 85% at 10 nM after 14 days of treatment^[3].
20-Hydroxyvitamin D3 (100 nM; 26 d) inhibits proliferation of MCF7 human breast carcinoma cells in soft agar, reducing CFU of colonies larger than 0.2 mm by 78% at 100 nM after 26 days of treatment^[3].
20-Hydroxyvitamin D3 (0.1 μM; 14 days, added every 72 h) significantly inhibits monolayer colony formation of SKMel-188 human melanoma cells^[4].
20-Hydroxyvitamin D3 (1-100 nM; 12 days, added every 72 h) dose-dependently inhibits anchorage-independent colony formation of SKMel-188 human melanoma cells, with IC₅₀ values ranging from 6.91 to 19.54 nM across colony size categories^[4].
20-Hydroxyvitamin D3 (10-100 nM; 24 h) dose-dependently inhibits chemotactic migration of SKMel-188 human melanoma cells at both 10,000 and 100,000 cells/well densities^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.